📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Neutrolis

1.1 - Company Overview

Neutrolis Logo

Neutrolis

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of candidate-stage, first-in-class anti-NET therapies, including the exDNASETM platform to create molecules that disassemble Neutrophil Extracellular Traps; NTR-L303 to resolve hyperinflammation and disrupt NET-immune complexes; NEU-101 for surface inflammation; and NET biomarkers to identify, treat, and monitor responsive patients.

Products and services

  • NTR-L303: Candidate-stage therapeutic that aims to resolve hyperinflammation and disrupt NET–immune complexes, directly targeting NET activity implicated in immune-mediated pathology
  • ExDNASETM platform: Custom-engineered platform that creates molecules to disassemble Neutrophil Extracellular Traps, addressing root causes of immune-mediated diseases and enabling anti-NETs therapeutics development
  • NET biomarkers: Precision-medicine biomarkers used to identify, guide treatment of, and monitor patients likely to respond to anti-NETs therapies

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Neutrolis

Rejuveron Logo

Rejuveron

HQ: Switzerland Website
  • Description: Provider of a fully integrated biotechnology platform that invests in people and ideas to develop therapies and technologies to improve healthy aging and prolong lifespan.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Rejuveron company profile →
PanGenetics Logo

PanGenetics

HQ: The Netherlands Website
  • Description: Provider of clinical development services for monoclonal antibodies targeting immune-mediated diseases, specializing in advancing candidates from late research stage through clinical proof of concept; based in Utrecht, the Netherlands, with an office in Cambridge, UK.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full PanGenetics company profile →
Adnexus Therapeutics Logo

Adnexus Therapeutics

HQ: United States Website
  • Description: Provider of discovery and development of Adnectins, a novel proprietary class of targeted biologics designed to block or stimulate therapeutic targets to fight diseases across a broad range of therapeutic areas; operates as a Bristol-Myers Squibb R&D company in the United States.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Adnexus Therapeutics company profile →
Skyepharma Logo

Skyepharma

HQ: United Kingdom Website
  • Description: Provider of specialty drug delivery using oral and inhalation technologies to create enhanced versions of existing pharmaceutical products and products with new chemical entities. Offers Geomatrix modified-release tablets, stick-pack unit-dose packaging, serialization and aggregation, formulation development, and cGMP clinical trial manufacturing.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Skyepharma company profile →
Confo Therapeutics Logo

Confo Therapeutics

HQ: Belgium Website
  • Description: Provider of GPCR-focused drug discovery solutions leveraging proprietary Confo® Technology and conformationally selective VHH ConfoBodies® to stabilize GPCRs in active, disease-relevant states. Offerings include ConfoScreen®, ConfoSensor®, and ConfoStructure™ for screening, biosensing, and structure-based design, and MegaBody™ for high-resolution cryo-EM, enabling novel medicine discovery and internal programs addressing unmet medical need.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Confo Therapeutics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Neutrolis

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Neutrolis

2.2 - Growth funds investing in similar companies to Neutrolis

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Neutrolis

4.2 - Public trading comparable groups for Neutrolis

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Neutrolis

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Neutrolis

What does Neutrolis do?

Neutrolis is a provider of candidate-stage, first-in-class anti-NET therapies, including the exDNASETM platform to create molecules that disassemble Neutrophil Extracellular Traps; NTR-L303 to resolve hyperinflammation and disrupt NET-immune complexes; NEU-101 for surface inflammation; and NET biomarkers to identify, treat, and monitor responsive patients.

Who are Neutrolis's competitors?

Neutrolis's competitors and similar companies include Rejuveron, PanGenetics, Adnexus Therapeutics, Skyepharma, and Confo Therapeutics.

Where is Neutrolis headquartered?

Neutrolis is headquartered in United States.

How many employees does Neutrolis have?

Neutrolis has 1,000 employees 🔒.

When was Neutrolis founded?

Neutrolis was founded in 2010 🔒.

What sector and industry vertical is Neutrolis in?

Neutrolis is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Neutrolis

Who are the top strategic acquirers in Neutrolis's sector and industry

Top strategic M&A buyers and acquirers in Neutrolis's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Neutrolis?

Top strategic M&A buyers groups and sectors for Neutrolis include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Neutrolis's sector and industry vertical

Which are the top PE firms investing in Neutrolis's sector and industry vertical?

Top PE firms investing in Neutrolis's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Neutrolis's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Neutrolis's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Neutrolis's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Neutrolis include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Neutrolis's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Neutrolis?

The key public trading comparables and valuation benchmarks for Neutrolis include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Neutrolis for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Neutrolis with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Neutrolis's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Neutrolis with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Neutrolis's' sector and industry vertical?

Access recent funding rounds and capital raises in Neutrolis's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Neutrolis